Avacta Group (AVCT) Competitors GBX 40.60 -0.40 (-0.98%) As of 02/21/2025 11:46 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines AVCT vs. SLN, PRTC, OXB, HZD, VRP, FARN, ARIX, BVXP, 4BB, and CIRShould you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Arix Bioscience (ARIX), Bioventix (BVXP), 4basebio (4BB), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry. Avacta Group vs. Silence Therapeutics PureTech Health Oxford Biomedica Horizon Discovery Group plc (HZD.L) Verona Pharma plc (VRP.L) Faron Pharmaceuticals Oy Arix Bioscience Bioventix 4basebio Circassia Group Avacta Group (LON:AVCT) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk. Does the MarketBeat Community prefer AVCT or SLN? Avacta Group received 9 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 68.81% of users gave Silence Therapeutics an outperform vote while only 67.30% of users gave Avacta Group an outperform vote. CompanyUnderperformOutperformAvacta GroupOutperform Votes21267.30% Underperform Votes10332.70% Silence TherapeuticsOutperform Votes20368.81% Underperform Votes9231.19% Do insiders & institutionals hold more shares of AVCT or SLN? 10.2% of Avacta Group shares are owned by institutional investors. 32.9% of Avacta Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer AVCT or SLN? In the previous week, Avacta Group had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 beat Avacta Group's score of -1.05 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Avacta Group Negative Silence Therapeutics Neutral Is AVCT or SLN more profitable? Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -114.45%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.Company Net Margins Return on Equity Return on Assets Avacta Group-114.45% -74.00% -21.80% Silence Therapeutics N/A N/A N/A Which has stronger valuation & earnings, AVCT or SLN? Silence Therapeutics has lower revenue, but higher earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvacta Group£26.29M5.87-£30.08M-£7.77-5.22Silence Therapeutics£11.35M0.00N/A-£48.60N/A SummaryAvacta Group beats Silence Therapeutics on 7 of the 12 factors compared between the two stocks. Get Avacta Group News Delivered to You Automatically Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVCT vs. The Competition Export to ExcelMetricAvacta GroupBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£154.24M£117.95M£5.84B£2.64BDividend Yield3.97%3.69%4.75%4.98%P/E Ratio-5.223.2026.04162.45Price / Sales5.874,826.69447.46313,322.68Price / Cash15.0013.0138.0128.12Price / Book2.7647.077.645.16Net Income-£30.08M-£87.82M£3.18B£5.75B7 Day Performance-7.97%0.34%-2.00%-0.99%1 Month Performance-14.64%3.63%-0.44%-0.80%1 Year Performance-47.27%99.15%16.44%39.55% Avacta Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVCTAvacta GroupN/AGBX 40.60-1.0%N/A-53.9%£154.24M£26.29M-5.22120SLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumePRTCPureTech Health2.0093 of 5 starsGBX 146.40+0.3%GBX 455+210.8%-24.1%£439.76M£521,320.79-6.01300News CoverageGap UpOXBOxford Biomedica2.519 of 5 starsGBX 387-0.5%GBX 433.33+12.0%+102.0%£411.39M£98.31M-2.88891News CoverageHZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416VRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpFARNFaron Pharmaceuticals OyN/AGBX 168.50+0.6%N/A+32.3%£226.21MN/A-4.5134ARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919BVXPBioventixN/AGBX 2,900-0.9%N/A-41.7%£151.85M£13.65M18.7612Negative News4BB4basebioN/AGBX 1,120flatN/A+52.3%£143.47M£311,000.00-1,435.90101CIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down Related Companies and Tools Related Companies Silence Therapeutics Alternatives PureTech Health Alternatives Oxford Biomedica Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Verona Pharma plc (VRP.L) Alternatives Faron Pharmaceuticals Oy Alternatives Arix Bioscience Alternatives Bioventix Alternatives 4basebio Alternatives Circassia Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:AVCT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avacta Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVCT Stock Alerts